AbbVie

1668 articles about AbbVie

• 

  AbbVie Continues Buying Spree with $8.7B Cerevel Acquisition to Bolster Neuro

  12/7/2023

  The deal, announced late Wednesday, will provide AbbVie with access to Cerevel Therapeutics’ pipeline of clinical-stage and preclinical candidates for psychiatric and neurological diseases.
• 

  The Top 12 Biopharma Companies Hiring Now

  12/6/2023

  As the end of 2023 approaches, hiring has slowed down further and in our most recent survey, fewer companies report that they are actively recruiting.

• AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

  12/6/2023

  AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.

• AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

  12/5/2023

  AbbVie Inc. (NYSE: ABBV) and BigHat Biosciences, today announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience.

• 

  ADC and GLP-1 Rocket Ride Continues as 2023 Comes to Close

  12/1/2023

  AbbVie’s $10.1 billion ImmunoGen buy and Altimmune’s Phase II win demonstrate that the antibody-drug conjugate market is red hot in cancer and GLP-1 drugs for weight loss are an absolute craze.
• 

  AbbVie Gets Phase II NSCLC Win for ADC, Looks to Accelerated Approval

  12/1/2023

  The company’s investigational c-Met protein directed antibody-drug conjugate showed a “compelling” overall response rate in patients with previously treated non-small cell lung cancer.

• AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

  11/30/2023

  AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).

• 

  AbbVie Buys ImmunoGen in $10B Deal, Gains Access to ADC for Ovarian Cancer 

  11/30/2023

  Facing the loss of Humira revenues from biosimilar competition, AbbVie is looking to grow its pipeline by acquiring ImmunoGen and its antibody-drug conjugate Elahere, which was granted FDA accelerated approval last year. 

• AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

  11/29/2023

  AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).

• AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

  11/27/2023

  AbbVie (NYSE: ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed or refractory (R/R) follicular lymphoma (FL).

• 

  Biologics Projected to Keep Gaining Ground in Cancer Therapeutics Market

  11/22/2023

  The market size for biologic oncology therapies will reach $786 billion by 2029, far outstripping small molecules, a GlobalData report predicts.
• 

  ASH Preview: Darzalex Faspro in Multiple Myeloma, Imbruvica-Venclexta in Mantle Cell Lymphoma

  11/22/2023

  J&J, AbbVie, Genmab and Genentech are presenting new data at next month’s American Society of Hematology meeting on the therapeutic potential of their therapies in multiple myeloma and mantle cell lymphoma.
• 

  AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study

  11/17/2023

  When given hours ahead of an expected episode, a late-stage study showed the preventive benefits of Ubrelvy in safely reducing moderate or severe headaches within 24 hours of treatment.

• Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine

  11/16/2023

  AbbVie (NYSE: ABBV) today announced detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome of a migraine attack.

• Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap

  11/1/2023

  Aldeyra Therapeutics, Inc. today announced that it has entered into an exclusive option agreement with AbbVie Inc. (AbbVie).

• BioMed X and AbbVie Start New Research Project in the USA

  10/31/2023

  BioMed X, an independent biomedical research institute, announces the start of a research project in collaboration with AbbVie to be hosted by the new BioMed X Institute in New Haven, CT, USA.

• NEXGEL Secures Supply Agreement with AbbVie

  10/30/2023

  NEXGEL, Inc. announced that its subsidiary, CG Converting and Packaging, has executed a supply agreement with AbbVie Inc., a global biopharmaceutical company to be a supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite.

• AbbVie Reports Third-Quarter 2023 Financial Results

  10/27/2023

  AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023.

• Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network

  10/24/2023

  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ ® ) in individuals living with systemic lupus erythematosus (SLE).

• 

  AbbVie’s Skyrizi Beats Remission Rates of J&J’s Stelara in Crohn’s Disease

  10/17/2023

  In a follow-up readout, data from the head-to-head SEQUENCE study showed that AbbVie’s Skyrizi induced better rates of steroid-free remission in Crohn’s disease than Johnson & Johnson’s Stelara.